Back to search results

A Study of Artesunate for Pulmonary Arterial Hypertension

This study is looking at the safety and how well people tolerate a medicine called artesunate in adults with Pulmonary Arterial Hypertension (PAH), a condition where blood pressure in the arteries of the lungs is too high. You might be able to join if you are between 18 and 75 years old and have PAH that is not fully controlled by other treatments. Participants will take artesunate capsules daily, with the dose gradually increasing over time. The main goal is to see how many participants experience side effects or serious side effects over 16 weeks. The study plans to enroll 15 participants, but its current recruitment status is unclear.

Study design
This is a Phase 1, single-center, open-label study, meaning both you and the study team will know you are receiving artesunate. It will involve a small group of 15 participants, with the dose of artesunate increasing over time.
What's involved
You would take artesunate capsules three times a day, with the dose gradually increasing. The study will last for 20 weeks.
Compensation
Not stated in the trial record.
Follow-up
The main safety information will be collected for 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06872112

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Recruiting
PHASE1Ages 18–60InterventionalTreatment
Joseph C. Wu
~15 participants
Updated 2026-04-23 on ClinicalTrials.gov
What's tested:Artesunate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over 16 weeks

Conditions

Pulmonary Arterial Hypertension (PAH)

Explore related trials

Pulmonary Arterial Hypertension

NCT06872112

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford University

    Stanford, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Roham Zamanian, MD · STUDY_DIRECTOR · Stanford University

Who to contact

Roham Zamanian, MD
[email protected]
(650) 725-7061
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Each participant must meet the following criteria to be enrolled in this study:
Adults aged 18 to 75 years.
WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.

Exclusion

Participants who meet any of the following criteria will be excluded from the study.
Participants with serious concomitant morbidity per investigator assessment.

What this trial measures

  • Number of Participants with treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs)16 weeks